论文部分内容阅读
目的:哮喘会带来实际的生产力损失和活动损伤,尤其在那些最严重的患者中。文章试图在重度或难治性哮喘患者中对《工作生产力和活动损伤问卷哮喘专用版本》(《WPAI:Asthma》)的性能进行评价。方法:分析了来自“哮喘流行病学和自然历史:结果及治疗方案(TENOR)研究”中的2529名研究对象,分别在基线和12个月随访期进行了《WPAI:Asthma》问卷评价。并分别使用哮喘治疗评价问卷(Asthma Therapy Assessment Questionnaire)和最低哮喘生活质量问卷(Mini-Asthma Quality-of-life Questionnaire)评价哮喘控制和生命质量。结果:重度哮喘与轻至中度哮喘相比,有较高比例的工作(28%∶14%)、学习(32%∶18%)和日常活动(41%∶21%)损伤。在基线WPAI测量出,较大的哮喘控制问题与较高水平的损伤相关(工作:r=0.54,学习:r=0.37,活动:r=0.55)。在12个月随访期间,改善生命质量与降低损伤水平相关(工作:r=-0.42,学习:r=-0.36,活动:r=-0.48)。在多元分析中,大于基线总体损伤10%即可预测在12个月随访期看急诊(OR2.6[1.6,4.0])和住院(OR4.9[1.8,13.1])的情况。结论:对于重度或难治性哮喘,《WPAI:Asthma》与其它预期方式自我报告的哮喘结果相关,它还可以预测12个月随访期的医疗服务利用。
Purpose: Asthma can result in actual loss of productivity and activity, especially in those who are most severe. This article attempts to evaluate the performance of “WPAI: Asthma” in patients with severe or refractory asthma. METHODS: A total of 2529 subjects from the “Epidemiology and Natural History of Asthma: TENOR Study” were analyzed for “WPAI: Asthma” questionnaire evaluation at baseline and at 12-month follow-up . Asthma Control Assessment Questionnaire and Mini-Asthma Quality-of-Life Questionnaire were used to evaluate asthma control and quality of life. RESULTS: Severe asthma had a higher proportion of work (28%: 14%), learning (32%: 18%), and daily activities (41%: 21%) compared with mild to moderate asthma. At baseline, WPAI measured that larger asthma control problems were associated with higher levels of impairment (work: r = 0.54, learning: r = 0.37, activity: r = 0.55). During 12 months of follow-up, improving quality of life was associated with a lower level of impairment (study: r = -0.42, study: r = -0.36, activity: r = -0.48). In a multivariate analysis, greater than 10% of baseline overall injury predicted an emergency (OR2.6 [1.6,4.0]) and hospitalization (OR4.9 [1.8,13.1]) at the 12-month follow-up. Conclusions: “WPAI: Asthma” is associated with other expected ways of self-reported asthma outcomes for severe or refractory asthma and predicts medical care utilization over a 12-month follow-up.